TYRA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.536

+24.71%

-0.562

+19.5%

-0.548

+16.67%

Estimates Revision

Stock Price

Go Up

+104.11%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast TYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TYRA is 31.33 USD with a low forecast of 28.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

28.00

Averages

31.33

High

36.00

Current: 0.000

Low

28.00

Averages

31.33

High

36.00

Wedbush

Robert Driscoll

maintain

$30 -> $37

2025-12-16

Reason

Wedbush

Robert Driscoll

Price Target

$30 -> $37

2025-12-16

maintain

Reason

Wedbush analyst Robert Driscoll raised the firm's price target on Tyra Biosciences to $37 from $30 and keeps an Outperform rating on the shares. The firm also added the name to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Phase 2 studies in intermediate-grade non-muscle invasive bladder cancer and in achondroplasia.

Goldman Sachs

initiated

2025-12-04

Reason

Goldman Sachs

Price Target

2025-12-04

initiated

Reason

Goldman Sachs initiated coverage of Tyra Biosciences with an Early-Stage Biotech rating. Tyra is a clinical stage biotechnology company using its proprietary drug-discovery platform to develop precision medicines to address significant unmet need, the analyst tells investors in a research note.

Oppenheimer

Matthew Biegler

Outperform

maintain

$30 -> $36

2025-09-10

Reason

Oppenheimer

Matthew Biegler

Price Target

$30 -> $36

2025-09-10

maintain

Outperform

Reason

Oppenheimer analyst Matthew Biegler raised the firm's price target on Tyra Biosciences to $36 from $30 and keeps an Outperform rating on the shares after hosting the company for meetings in Boston on Monday. In each meeting, management made the case for why dabogratinib's combined market opportunity exceeds $10B. That's nearly Regeneron-esque revenues. Despite that, investors still complain that all the major catalysts aren't until 2026. NULLtheless, the firm tells investors, \"don't expect to find shares at this price - with a sub-$500M enterprise value - next year.\"

Raymond James

analyst

Strong Buy

initiated

$35

2025-09-02

Reason

Raymond James

analyst

Price Target

$35

2025-09-02

initiated

Strong Buy

Reason

Raymond James initiated coverage of Tyra Biosciences with a Strong Buy rating and $35 price target. Tyra's unique SNAP development platform, as validated with the first discovery candidate, TYRA-300, is "potentially best-in-class," says the analyst, who sees "multi-billion-dollar revenue potential" in the indications being investigated.

Piper Sandler

Allison Bratzel

Overweight

initiated

$33

2025-05-21

Reason

Piper Sandler

Allison Bratzel

Price Target

$33

2025-05-21

initiated

Overweight

Reason

Piper Sandler analyst Allison Bratzel assumed coverage of Tyra Biosciences with an Overweight rating and $33 price target. The firm cites the "promising data to date" for the company's lead asset TYRA-300 in metastatic urothelial carcinoma and upcoming key expansion opportunities into achondroplasia and non-muscle invasive bladder cancer for the Overweight rating. By targeting FGFR3 with high selectivity over other FGFRs, TYRA-300's profile is emerging as safer and more efficacious than current pan-FGFR inhibitors with low therapeutic windows and significant toxicities, the analyst tells investors in a research note.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$30

2025-03-31

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$30

2025-03-31

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Tyra Biosciences Inc (TYRA.O) is -12.07, compared to its 5-year average forward P/E of -8.72. For a more detailed relative valuation and DCF analysis to assess Tyra Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.72

Current PE

-12.07

Overvalued PE

-4.26

Undervalued PE

-13.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.46

Current EV/EBITDA

-7.86

Overvalued EV/EBITDA

12.32

Undervalued EV/EBITDA

-19.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1354.65% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 1354.65% over the last month.

Sold

Bought

TYRA News & Events

Events Timeline

No data

News

5.0

2025-12-23Fool

Tyra Biosciences Director Sells 246,871 Shares for $5 Million

5.0

2025-12-23NASDAQ.COM

Tyra Biosciences Director Sells 246,871 Shares, Retains $77.6 Million Stake

6.0

2025-12-16Benzinga

Accenture Set to Surge Over 16%? Check Out 10 Leading Analyst Predictions for Tuesday

People Also Watch

Frequently Asked Questions

What is Tyra Biosciences Inc (TYRA) stock price today?

The current price of TYRA is 29.31 USD — it has decreased -3.43 % in the last trading day.

What is Tyra Biosciences Inc (TYRA)'s business?

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

What is the price predicton of TYRA Stock?

What is Tyra Biosciences Inc (TYRA)'s revenue for the last quarter?

Tyra Biosciences Inc revenue for the last quarter amounts to -32.94M USD, increased 15.17 % YoY.

What is Tyra Biosciences Inc (TYRA)'s earnings per share (EPS) for the last quarter?

Tyra Biosciences Inc. EPS for the last quarter amounts to -22419000.00 USD, increased 24.90 % YoY.

What changes have occurred in the market's expectations for Tyra Biosciences Inc (TYRA)'s fundamentals?

The market is revising No Change the revenue expectations for TYRA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 104.11%.

How many employees does Tyra Biosciences Inc (TYRA). have?

Tyra Biosciences Inc (TYRA) has 60 emplpoyees as of January 11 2026.

What is Tyra Biosciences Inc (TYRA) market cap?

Today TYRA has the market capitalization of 1.56B USD.